Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab ...

Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI ...

Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

Pfizer Inc. announced positive topline results from the phase 3 BASIS study (NCT03938792) evaluating Hympavzi (marstacimab) for adults and adolescents living with haemophilia A or B with inhibitors.

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint ...

Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...